The US Food and Drug Administration (FDA) has released a final guidance document with immediate effect advising sponsors on ...
The core principle of BETMAT’s Kinetic Chromogenic LAL Assay is based on the specific enzymatic cascade triggered by the interaction between Limulus Amebocyte Lysate (LAL) and bacterial ...
When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...
“I just need you to validate my feelings.” It's a phrase therapists, partners, and friends hear constantly—and it reveals something fascinating about our cultural moment. Validation has become the ...
New blood tests measuring p-tau217 levels show promise for predicting Alzheimer's risk years before symptoms appear, though ...
Expert insights on QMSR compliance: transition steps, gap assessments, risk-based approach, and global harmonization with ISO ...
Over the past year, we have carefully considered whether — and how — life sciences companies can use AI tools in their clinical development ...
Morning Overview on MSN
FDA to pilot real-time tracking of clinical trials to speed safety feedback
When a patient in an early-phase drug trial experiences a serious side effect today, weeks or even months can pass before ...
The FDA Process Validation training highlights opportunities in enhancing comprehension of constant process verification aligned with lifecycle concepts. It addresses early R&D phases through ...
On March 18 th, the FDA published draft guidance on validating new approach methodologies (NAMs), including complex in vitro models (CIVMs). For a field long operating without a clear regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results